Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay
B. Siegall, Ph.D., President and Chief Executive Officer, will
present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday,
January 12, 2015, at 11:30 a.m. Pacific Time. The presentation will be
webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com
in the Investors
and News section.
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development
and commercialization of innovative antibody-based therapies for the
treatment of cancer. Seattle Genetics is leading the field in developing
antibody-drug conjugates (ADCs), a technology designed to harness the
targeting ability of antibodies to deliver cell-killing agents directly
to cancer cells. The company’s lead product, ADCETRIS®
(brentuximab vedotin), is an ADC that, in collaboration with Takeda
Pharmaceutical Company Limited, is commercially available for two
indications in more than 45 countries, including the U.S., Canada, Japan
and members of the European Union. Additionally, ADCETRIS is being
evaluated broadly in more than 30 ongoing clinical trials. Seattle
Genetics is also advancing a robust pipeline of clinical-stage ADC
programs, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME
and ASG-15ME. Seattle Genetics has collaborations for its ADC technology
with a number of leading biotechnology and pharmaceutical companies,
including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech,
GlaxoSmithKline and Pfizer. More information can be found at www.seattlegenetics.com.
Copyright Business Wire 2015